These BSPED guidelines are believed to be as safe as possible in the light of current evidence.However, no guidelines can be considered entirely safe as complications may still arise. In particularthe pathophysiology of cerebral oedema is still poorly understood (the British Society for Paediatric Endocrinology and Diabetes)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
IWGDF Guidelines on the prevention and management of diabetic foot disease
The International working Group on the Diabetic Foot (IWGDF) has been producing evidence-based guidelines on the prevention and management of diabetic foot disease since 1999. In 2019, all IWGDF Guidelines have been updated, based on systematic reviews of the literature and formulation of recommendations by multidisciplinary experts from all over the world (International Working Group on the Diabetic Foot (IWGDF) )
A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial
A novel rapid insulin-and-pramlintide artificial pancreas improves glucose control compared with a rapid insulin-alone artificial pancreas (Diabetes Care)
The cost of prevalent and incident cardiovascular disease in people with type 2 diabetes in Scotland: data from the Scottish Care Information–Diabetes Collaboration
Cardiovascular disease in people with type 2 diabetes places a significant financial burden on healthcare and the wider economy. Our results emphasize the financial consequences of cardiovascular disease prevention strategies (Diabetic Medicine)
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
This second part of this 2-part review summarizes the findings of recent clinical trials and their clinical implications and describes ongoing trials and future areas of research (Journal of the American College of Cardiology)
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
This first part of this 2-part review provides an overview of the current understanding of the mechanisms of the cardio-metabolic-renal benefits of SGLT2i. The second part summarizes the recent clinical trials of SGLT2i (Journal of the American College of Cardiology)
Liraglutide as add‐on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial
Liraglutide significantly improved glycaemic control compared to placebo in patients with type 2 diabetes, insufficiently controlled with SGLT2is with/without metformin, with no unexpected safety findings (Diabetes, Obesity and Metabolism)
Smartphone-Based Technology in Diabetes Management
So far, regardless of the limitations of the available studies, most of the reviewed mobile medical applications have been shown to positively effect outcomes, including HbA1c levels and hypoglycemia rates (Diabetes Therapy)
Socio‐economic status and mortality in people with type 1 diabetes in Scotland 2006–2015: a retrospective cohort study
Socio‐economic deprivation was associated with a steeper mortality gradient in people with type 1 diabetes than in the population without type 1 diabetes in Scotland. Age‐standardized mortality has decreased over time but socio‐economic inequalities may be increasing. (Diabetic Medicine)
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration. Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity. EMPA could therefore contribute to the early treatment of nonalcoholic fatty liver disease in T2D (Diabetes Care)
How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?
The deeper analysis of data from the well-powered SWITCH studies does support that the new IHSG level 2 definition compared with the previous ADA definition can result in statistically more robust findings when comparing insulins (Diabetes Care)
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
It is time to include NASH in the management plan of patients with T2D in the same way as today it includes diabetic retinopathy or nephropathy (Diabetes Care)
Guidelines of the international writing group on the diabetic foot on diagnosis
We here present the updated 2019 guidelines on diagnosis, prognosis, and management of PAD in patients with a foot ulcer and diabetes, and we suggest some key future topics of particular research interest (Diabetes/Metabolism Research and Reviews)
Comparative effects of sulfonylureas, DPP4is and SGLT2 inhibitors added to metformin monotherapy: a propensity‐score matched cohort study in UK primary care
In routine care, SGLT2is have greater effects on cardiometabolic risk factors than SUs. Routine care data closely replicates the effects of diabetes drugs on physiological variables measured in clinical trials (Diabetes, Obesity and Metabolism)
Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers
The American Diabetes Association’s (ADA’s) Standards of Medical Care in Diabetes is updated and published annually in a supplement to the January issue of Diabetes Care
The future of prevention of diabetic foot ulcer: A paradigm shift from stratified healthcare towards personalized medicine
Diabetic foot ulcer prevention is still underexposed in research and clinical practice, despite that all working in diabetic foot care agree that it is highly important. In this article, we identified a number of barriers that, in our opinion, prevent prioritizing ulcer prevention (Diabetes/Metabolism Research and Reviews)
Effects of Intermittent Fasting on Health, Aging, and Disease
Preclinical studies and clinical trials have shown that intermittent fasting has broad-spectrum benefits for many health conditions, such as obesity, diabetes mellitus, cardiovascular disease, cancers, and neurologic disorders (NEJM)
Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study
Nationwide unrestricted reimbursement of isCGM in people with type 1 diabetes treated in specialist diabetes centers results in higher treatment satisfaction, less severe hypoglycemia, and less work absenteeism, while maintaining quality of life and HbA1c (Diabetes Care)
A qualitative study of clinician attitudes towards closed‐loop systems in mainstream diabetes care in England
Clinicians recognize the value of closed‐loop systems in terms of health benefits, but also identify a range of concerns for both users and healthcare staff, which could impact negatively on user access (Diabetic Medicine)
Assessing the Risk for Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes
Adults with type 2 diabetes prescribed an SGLT2 inhibitor had a lower rate of gout than those prescribed a GLP1 agonist. Sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout among adults with type 2 diabetes mellitus, although future studies are necessary to confirm this observation (Annals of Internal Medicine)
Glycosmedia is also available as an App: